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186resynchronization therapy was instituted in 17% (100 of 577) and
percutaneous coronary revascularization in 10% (58 of 577) of
unoperated patients. At the end of follow-up, the severity of MR
improved to less than grade 2þ in 15% of patients (89 of 577).
In the Euro Heart Survey (396 patients with severe MR), 56%
and 32% of patients with DMR and FMR, respectively, did not
undergo surgery (4). In contrast, we found that the majority of
patients with DMR underwent surgery and the vast majority (90%)
of unoperated patients had FMR. This likely reﬂects the low risk
and better durability of surgical MV repair for DMR compared
with FMR in a center with surgical expertise and excellence. In
contrast, many patients with FMR do not undergo MV surgery
unless coronary artery bypass grafting is feasible and indicated (77%
in our cohort of patients with ischemic FMR) when concomitant
MV surgery is usually performed.
The current class IIb recommendation for MV surgery in the
presence of LV dysfunction is based on lack of survival beneﬁt and a
high recurrence rate ofMR (5). The outcomes of medically managed
patients, however, remain understudied. Our observations highlight
the poor outcomes of medically managed patients with severe FMR
with a 1-year mortality rate of 20%, 5-year mortality rate of 50%,
and high rate of heart failure hospitalization. Until recently, medi-
cally managed patients with FMR had no good options short of
advanced mechanical support and heart transplantation. MitraClip
provides an important new tool for FMR with good clinical
improvement and safety (30-day mortality rate of 1%) (2). Non-
randomized studies have shown a clinical beneﬁt of MitraClip in
high-risk patients with FMR (3). Our study identiﬁes a potentially
large unmet need for transcatheter MR reduction strategies in
medically managed patients. In this context, the ongoing studies
that are enrolling high surgical risk patients with severe FMR will
provide data on the effectiveness of MitraClip in these patients.
This was a single-center observational study from a large tertiary
referral center. It is possible that some patients with severe MR
were hospitalized outside our network of hospitals, resulting in an
underestimation of hospitalization rates. Not all patients were
necessarily referred to a cardiothoracic surgeon. However, this
mirrors current clinical practice, where the role of surgery for FMR
remains nebulous. Finally, anatomic criteria for MitraClip are
evolving with increasing experience, underestimating the potential
applicability of this therapy.
In conclusion, our analysis not only highlights a substantial
unmet need for MitraClip for symptomatic patients with severe
MR but also provides some benchmark data on their outcomes
with medical management.Sachin S. Goel, MDy
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Computed Tomography for
Diagnosis of Prosthetic
Valve Endocarditis
Increased Valvular 18F-Fluorodeoxyglucose
Uptake as a Novel Major CriterionWe read with great interest the recent publication by Saby et al. (1),
in which 72 patients with suspected prosthetic heart valve (PHV)
endocarditis were prospectively studied to determine the accuracy
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187of positron emission tomography (PET)/computed tomography
(CT) to diagnose PHV endocarditis and the complementary value
of PET/CT as a major criterion in the modiﬁed Duke criteria. The
sensitivity and speciﬁcity of ﬂuorodeoxyglucose (FDG)-PET for
PHV endocarditis were 73% and 80%, respectively. When PET/
CT was added as a new major criterion to the modiﬁed Duke
criteria, the sensitivity rose from 70% to 97%. Clinically, the results
of this study are very important because PHV endocarditis is still
missed by echocardiography in up to 30% of cases (2,3). However,
the present study raises concerns about the speciﬁcity numbers,
early post-operative PHV endocarditis, and low sensitivity of
PET/CT imaging for vegetations.
A serious concern is the speciﬁcity of PET/CT because no PHV
controls were included as opposed to other similar studies con-
cerning the diagnostic value of FDG uptake around the implanted
cardiac devices (4,5). A normal FDG uptake pattern is crucial for
interpretation of the speciﬁcity and standardized uptake values
reported by Saby et al. (1), especially in the early post-operative
phase (<1 year). In this time frame, post-operative inﬂammation
may be a major issue and could result in false-positive imaging. The
authors did not discuss this point, probably because the median
post–PHV implantation period was 1,484 days (interquartile range:
526 to 3,396 days). As a consequence, the diagnostic value of PET/
CT in the early post-operative PHV phase was not investigated.
Furthermore, the authors did not elaborate on the role of retro-
spective electrocardiogram (ECG)-gated CT angiography (CTA)
for the detection of PHV endocarditis (6–8). Fagman et al. (6)
showed in a surgically conﬁrmed subpopulation of their study that
CTA was able to provide good detectability of both vegetations and
abscesses in patients with PHV endocarditis. CTA combined with
transesophageal echocardiography improved the diagnostic accuracy
of the imaging even more. In contrast, the results of the present
study showed that PET/CT missed a substantial number of vege-
tations (9 of 20 [45%]) in cases with no other echocardiographic
signs of PHV endocarditis. The authors discussed that this low
sensitivity of PET/CT for vegetations was caused by its low spatial
resolution. In our opinion, another reason for missing vegetations
was probably the high mobility of the valve leaﬂets resulting in
blurring of the PET signal beyond the point of detectability. The
moderate performance of PET/CT in the detection of anatomic
substrates can be substantially improved by CTA, which provides
both better spatial and temporal resolution compared with PET/CT
(which employs non–ECG-gated unenhanced low-dose CT).
This raises the question whether patients with a high suspicion of
PHV endocarditis and negative or inconclusive echocardiography
should undergo CTA or FDG-PET/CT. One could even argue that
combining both techniques is justiﬁed in a patient category with a
high in-hospital mortality (9). In our opinion, a tailor-made decision
has to be made on which technique should be used and what addi-
tional imaging is necessary. For example, in patientswith renal failure,
an additional PET/CT scan may be favorable; however, in patients
with an aortic PHV vegetation and suspected abscess, a CTA is
preferable because it may also provide noninvasive coronary angiog-
raphy. This may replace pre-operative invasive coronary angiography,
which is not desirable in a patient with aortic PHVvegetations (8,10).
In conclusion, FDG-PET imaging is a promising and welcome
new imaging tool for PHV endocarditis. However, speciﬁcity is a
concern because normal FDG uptake around PHVs, in particular
early after operation, is not known. Therefore, the proposed
addition of PET/CT to the Duke criteria as a major criterion is to
our opinion too premature. Furthermore, the sensitivity of FDG-PET for the detection of anatomic abnormalities such as vegeta-
tions is poor and needs to be compared with that of CTA.*Wilco Tanis, MD
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Computed Tomography for Diagnosis
of Prosthetic Valve EndocarditisWe thank Dr. Tanis and colleagues for their comments with regard
to our recently published report (1). They raised 3 important points
that we would like to discuss.
